Business / Finance RSS Feed - Business / Finance

The new Micronic handheld wireless scanner MINI enables users to reliably read1D and 2D tube and rack codes almost instantly. Measuring just 135 x 41 x 30mm and weighing only 80g, this small lightweight device is practical to carry around, easy-to-use and can read any 1D barcode or 2D Data-Matrix code on 24-, 48- and 96-well format tubes and rack

Users can now wirelessly read barcodes from Micronic or other brands of tubes and ANSI / SLAS* format compatible racks anywhere in their lab or in the field. A high capacity lithium polymer battery provides a long lasting minimum of 15,000 2D scans or approximately 17,000 ID scans per charge. [More]

The new Micronic handheld wireless scanner MINI enables users to reliably read1D and 2D tube and rack codes almost instantly. Measuring just 135 x 41 x 30mm and weighing only 80g, this small lightweight device is practical to carry around, easy-to-use and can read any 1D barcode or 2D Data-Matrix code on 24-, 48- and 96-well format tubes and rack

Users can now wirelessly read barcodes from Micronic or other brands of tubes and ANSI / SLAS* format compatible racks anywhere in their lab or in the field. A high capacity lithium polymer battery provides a long lasting minimum of 15,000 2D scans or approximately 17,000 ID scans per charge. [More]
Milestones in microCT development: an interview with Alexander Sasov, CEO, Bruker MicroCT

Milestones in microCT development: an interview with Alexander Sasov, CEO, Bruker MicroCT

MicroCT (micron-scale computed tomography) technology was completely unknown when it began to be commercially available more than 15 years ago.... [More]
Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International plc today reported fourth quarter 2014 revenues of $800 million, an increase of 37 percent compared to fourth quarter 2013 revenues of $585 million, including new product revenue from 2014 strategic M&A transactions. [More]
BioScrip’s total revenue increases $28.2 million to 2.5% in fourth quarter 2014

BioScrip’s total revenue increases $28.2 million to 2.5% in fourth quarter 2014

BioScrip®, Inc. today announced 2014 fourth quarter financial results. Fourth quarter revenue from continuing operations was $253.7 million and the net loss from continuing operations was $61.9 million, or $0.90 per basic and diluted share. [More]
Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen. [More]
BioMed Realty recaptures valuable properties in Cambridge innovation district

BioMed Realty recaptures valuable properties in Cambridge innovation district

BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has recaptured approximately 313,000 square feet of space in the most dynamic and valuable life science real estate market in the world through the termination of Vertex Pharmaceuticals' leases on three properties in Cambridge, Massachusetts effective February 28, 2015. [More]

PTI Launches Game-based Learning for the Pharma, Biotech and Medical Device Industries

Pharmaceutical Training International (PTI), the leading supplier of online and public, event-based training courses for the pharma, biotech and medical device sectors, has launched a range of game-based e-learning courses. [More]
Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. [More]
Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

A paper published today, "Financing translation: Analysis of the NCATS rare-diseases portfolio" in Science Translational Medicine, demonstrates the potential of a new financing technique to reduce the risk associated with investing in the treatment of new diseases and potentially unlock new levels of funding for developing so-called "orphan" drugs. [More]

Covalon reports financial results for first quarter 2014

Covalon Technologies Ltd., an advanced medical technologies company, today announced financial results for its first quarter ended December 31, 2014. [More]
Intrexon signs agreement to acquire Okanagan Specialty Fruits

Intrexon signs agreement to acquire Okanagan Specialty Fruits

Intrexon Corporation, a leader in synthetic biology, today announced it has entered into an agreement to acquire Okanagan Specialty Fruits, the pioneering agricultural company behind the Arctic apple, the world's first non-browning apple. [More]
Mylan acquires non-U.S. developed markets specialty and branded generics business from Abbott

Mylan acquires non-U.S. developed markets specialty and branded generics business from Abbott

Mylan N.V. and Mylan Inc. today announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business. [More]

TxCell invited to speak at largest US meeting for investors in emerging growth companies

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference. [More]

ChartSpan Medical Technologies raises $1.7 million in capital round

ChartSpan Medical Technologies announced it has successfully raised a capital round of $1.7 million dollars. Since becoming the most downloaded iPhone and iPad medical app in the U.S. in December, ChartSpan continues to disrupt healthcare with innovative technology empowering patients to manage their own healthcare records and information. [More]
ERT signs definitive agreement to acquire PHT

ERT signs definitive agreement to acquire PHT

ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, and PHT Corporation, the eClinical innovator leading the adoption of patient-driven mobile apps for improved clinical research, announced today that they have signed a definitive agreement under which ERT will acquire PHT. [More]
Chiasma closes $70 million Series E financing round

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round. [More]
Omnicell agrees to purchase MACH4 Pharma Systems

Omnicell agrees to purchase MACH4 Pharma Systems

Omnicell, Inc., a leading provider of medication and supply management solutions to healthcare systems and pharmacies, today announced that it has signed an agreement to purchase MACH4 Pharma Systems, based in Bochum, Germany. [More]

Metrohm USA announces 2015 Young Chemist Award winner

Metrohm USA and Metrohm Canada are pleased to announce the winner of the 2015 Young Chemist Award, Chad Atkins. Chad is completing his Ph.D. at the University of British Columbia where he works under the supervision of Robin Turner and Michael Blades. [More]
Vectorious Medical Technologies closes $5 million financing round

Vectorious Medical Technologies closes $5 million financing round

Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round. [More]